MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks

Pulkkinen, Mari‐Anne; Varimo, Tero; Hakonen, Elina; Harsunen, Minna H; Hyvönen, Mervi E.; Janér, Joakim; Kiiveri, Sanne; Laakkonen, Hanne; Laakso, Saila; Wehkalampi, A Karoliina; Hero, Matti; Miettinen, Päivi J.; Tuomaala, Anna‐Kaisa

doi:10.1089/dia.2022.0313

Cited by 21 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that the health care and reimbursement systems in Latin America are very heterogeneous, we cannot assume an even distribution. On the other hand, personal interference with the MiniMed 780G system is low and together with the high glycaemic control as achieved in (real‐world) users from various countries, 7,10 with varying ages, 4,7,20,27 and with varying treatment histories, 5,21,25,26,28 this may be seen as a proof‐of‐concept that automation is the key to obtaining high glycaemic control (independently of socio‐demographic factors). Second, HbA1c could not be used as an endpoint as it cannot be directly derived from CGM data.…”

Section: Discussionmentioning

confidence: 99%

Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Grassi

Gómez

Calliari

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim We studied real‐world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), and the effect of each technology iteration of the MM system on glycaemic control (technology iteration analysis). Materials and Methods CareLink data from August 2020 to September 2022 were extracted. Endpoints included continuous glucose monitoring metrics. For the geographical analysis, aggregated endpoints for MM780G system users were calculated. For the technology iteration analysis, MM780G system user outcomes were compared with outcomes when the same individuals were still using the MM640G or MM670G system. Results On average, 1025 MM780G system users from the geographical analysis were followed for 136 (SD 135) days, spent 91.5 (14.3)% in advanced hybrid closed loop, showed a glucose management indicator (GMI) of 6.7 (0.3)%, a time in range between 70 and 180 mg/dl (TIR) of 76.5 (9.0)%, and a time below range 70 mg/dl (TBR) of 2.7 (2.1)%. The percentage of users reaching targets of GMI <7%, TIR >70% and TBR <4% was 80.8%, 78.1% and 80.1%, respectively. The technology iteration analysis on users transitioning from MM640G to MM780G system (N = 381) showed 0.4% decrease in GMI (7.1% to 6.7%, p < .0001), 10.7% increase in TIR (65.9% to 76.6%, p < .0001), while TBR remained. The percentage of insulin delivered automatically increased as well (47.5%‐57.7%, p < .0001). Users transitioning from MM670G system (N = 78) showed a similar but less pronounced pattern. Conclusions Real‐world Latin American MM780G users on average showed good glucose control, achieving international targets. Glycaemic control increased with every technology iteration of the MM system, providing more automation each time.

show abstract

Section: Discussionmentioning

confidence: 99%

Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Grassi

Gómez

Calliari

et al. 2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…HbA1c, mean sensor glucose (MSG) value and TAR decreased, TIR increased significantly (+8.3%), whereas no significant changes in time below range (TBR) was observed. MiniMed 780G was demonstrated to be a safe and effective system in 2- to 6-year-old children with type 1 diabetes and wase associated with a reduction in parental diabetes distress [ 59 ].…”

Section: Use Of Ahcl By Age Groupmentioning

confidence: 99%

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Bassi

Franzone

Dufour

et al. 2023

Life

View full text Add to dashboard Cite

Type 1 diabetes (T1D) patients’ lifestyle and prognosis has remarkably changed over the years, especially after the introduction of insulin pumps, in particular advanced hybrid closed loop systems (AHCL). Emerging data in literature continuously confirm the improvement of glycemic control thanks to the technological evolution taking place in this disease. As stated in previous literature, T1D patients are seen to be more satisfied thanks to the use of these devices that ameliorate not only their health but their daily life routine as well. Limited findings regarding the use of new devices in different age groups and types of patients is their major limit. This review aims to highlight the main characteristics of each Automated Insulin Delivery (AID) system available for patients affected by Type 1 Diabetes Mellitus. Our main goal was to particularly focus on these systems’ efficacy and use in different age groups and populations (i.e., children, pregnant women). Recent studies are emerging that demonstrate their efficacy and safety in younger patients and other forms of diabetes.

show abstract

“…Multiple studies have shown that closed‐loop systems enable better glycemic control measured in glycated hemoglobin (HbA1c), TIR, hyperglycemia, hypoglycemia, lower variability, and improved quality of life 3–8 …”

Section: Introductionmentioning

confidence: 99%

“…1,2 Multiple studies have shown that closed-loop systems enable better glycemic control measured in glycated hemoglobin (HbA1c), TIR, hyperglycemia, hypoglycemia, lower variability, and improved quality of life. [3][4][5][6][7][8] One of the closed-loop systems is the Medtronic MiniMed 780G device. It features an advanced hybrid closed-loop (AHCL) algorithm that includes automatic delivery of basal insulin every 5 min, adjustable targets of 100 (5.50), 110 (6.10), and 120 (6.70) mg/dL (mmol/L), and automatic delivery of correction boluses every 5 min.…”

Section: Introductionmentioning

confidence: 99%

Impact on glucometric variables and quality of life of the advanced hybrid closed‐loop system in pediatric and adolescent type 1 diabetes

Lendínez‐Jurado,

Gómez‐Perea,

Ariza‐Jiménez

et al. 2023

Journal of Diabetes

View full text Add to dashboard Cite

Background: In recent years, technological advances in the field of diabetes have revolutionized the management, prognosis, and quality of life of diabetes patients and their environment. The aim of our study was to evaluate the impact of implementing the MiniMed 780G closed-loop system in a pediatric and adolescent population previously treated with a continuous subcutaneous insulin infusion pump and intermittent glucose monitoring. Methods: Data were collected from 28 patients with type 1 diabetes aged 6 to 17 years, with a follow-up of 6 months. We included both glucometric and quality of life variables, as well as quality of life in primary caregivers. Metabolic control variables were assessed at baseline (before system change) and at different cutoff points after initiation of the closedloop system (48 hours, 7 days, 14 days, 21 days, 1 month, 3 months, 6 months). Results: Time in range 70-180 mg/dL increased from 59.44% at baseline to 74.29% in the first 48 hours after automation of the new system, and this improvement was maintained at the other cutoff points, as was time in hyperglycemia 180-250 mg/dL (24.44% at baseline to 18.96% at 48 hours) and >250 mg/dL (11.71% at baseline to 3.82% at 48 hours). Conclusions: Our study showed an improvement in time in range and in all time spent in hyperglycemia from the first 48 hours after the automation of the system, which was maintained at 6 months. K E Y W O R D S pediatric type 1 diabetes, advanced hybrid closed-loop, time in range, time in hyperglycemia, MiniMed 780G

show abstract

MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks

Cited by 21 publications

References 40 publications

Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Automated Insulin Delivery (AID) Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes and Other Forms of Diabetes in Europe in Early 2023

Impact on glucometric variables and quality of life of the advanced hybrid closed‐loop system in pediatric and adolescent type 1 diabetes

Contact Info

Product

Resources

About